

Cordlife Singapore responds to updates on FACT and AABB accreditations

Singapore, 7 December 2023: Cordlife Group Limited (“CGL”) announces an update on the status of its accreditations with FACT (Foundation for the Accreditation of Cellular Therapy) and AABB (Association for the Advancement of Blood & Biotherapies) for its facility in Singapore (“Cordlife Singapore”).

This is as a result of the ongoing investigation by the Ministry of Health (MOH), announced on [30 November](#). Cordlife Singapore continues to work closely with MOH on the ongoing investigation.

Update on FACT accreditation

FACT has notified Cordlife Singapore that, effective immediately, the company’s FACT accreditation is suspended indefinitely, at a minimum, until the ongoing investigations are completed and issues are resolved. This update will not impact the storage of cord blood units at Cordlife Singapore. Cordlife Singapore has maintained FACT accreditation for the past eight years.

Once the investigation with MOH has come to a conclusion, Cordlife Singapore will extend an invitation to FACT for a thorough inspection.

Update on AABB accreditation

Following Cordlife Singapore’s notification to AABB regarding the MOH investigation, the accreditation body has since issued a statement with their response, which can be found [here](#). This update will not impact the storage of cord blood units at Cordlife Singapore. Cordlife Singapore has maintained AABB accreditation for the past 18 years and is engaging with AABB, providing them with details about the ongoing investigation.

Statement from Ms. Tan Poh Lan, Group Chief Executive Officer, CGL:

“I once again want to convey my sincere apologies to our clients for any distress that this incident has caused. We are working hard to update them on their individual situations as quickly as we can, as well as address the questions and concerns they rightly have. Our conversations with the Ministry of Health are continuing and we hope to be able to provide further updates on our progress soon.”

“We will be working closely with FACT and AABB to share updates and information as the investigation with MOH progresses.”

END



For journalists only:

Media contact

Cognito for Cordlife

Cordlife@cognitomedia.com

+65 8404 8972

ABOUT CORDLIFE GROUP LIMITED Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), founded in 2001, is a leading company dedicated to safeguarding the well-being of mother and child. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia. Cordlife operates Asia’s largest network of cord blood banks. With full stem cell banking facilities in six key markets, Cordlife is an industry leader in Singapore, Hong Kong, Indonesia, and the Philippines and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife has an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. In addition to cord blood, cord lining, and cord tissue banking, Cordlife offers families a comprehensive suite of diagnostic services, including non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening. Two of Cordlife’s primary focus areas are providing reliable quality and being customer-centric. In the area of clinical diagnostics, Cordlife India and Healthbaby Hong Kong are both accredited by the College of American Pathologists (“CAP”). Healthbaby Hong Kong is the world’s only private cord blood bank to be accredited by three international standard-setting bodies, and Cordlife India is one of only two medical laboratories in West Bengal to be accredited by the National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and CAP. These quality achievements reinforce the Group’s commitment to providing reliable healthcare solutions through innovation and technological advancement. For more information, visit <http://cordlife.listedcompany.com>.